Skip to main content
Premium Trial:

Request an Annual Quote

Blurry Lines and the Cost Curve

"The line between computing and biology has begun to blur," says this New York Times article focusing on Complete Genomics' efforts to offer cheaper sequencing through the combination of biology, chemistry, and computing. The Times says that Complete Genomics' origin is "a classic Silicon Valley start-up story" — an entrepreneur with a background in physics and math partnering with an optical physicist to start a company that offers sequencing as a service, rather than selling machines. Of course, Complete Genomics has a number of competitors. The Times notes that "because there is no clear winner yet, all of the companies are pushing hard to get down the cost curve as fast as possible."

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.